Under one in 10 patients eligible to benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major obstacles to universal access to the treatments that can aid individuals in losing considerable body mass, notes the agency.
Weight-Loss Drug Supply Crisis
Despite the present best projected outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, according to the health organization.
The recommendation encourages countries and companies to increase availability, by approaches like patent sharing.
The intellectual property rights on semaglutide – the primary component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Jabs Function
These medications mimick a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so users consume fewer calories.
Individuals commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Evidence suggests patients may see weight return after a year of stopping the treatment, because their typical food cravings return.
To be carrying excess weight increases your chance for developing diseases, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity concerns people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the health agency.
